FBR Capital Starts Prima Biomed (PBMD) at Outperform

December 3, 2015 7:03 AM EST
Get Alerts PBMD Hot Sheet
Price: $1.71 --0%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE

FBR Capital initiates coverage on Prima Biomed (NASDAQ: PBMD) with a Outperform rating and a price target of $6.00.

Analyst Vernon Bernardino commented, "We are initiating coverage of Prima BioMed Ltd. (PBMD) with an Outperform rating and a price target of $6 per share. Whereas PBMD had one active clinical program in 2014, the company now has three novel product candidates in active clinical development, including IMP321, IMP731, and GSK 2831781, with the latter two rapidly being advanced by two partners committed to their full evaluation. We believe the current valuation of Prima BioMed is disconnected from our estimation of the significant value PBMD has created in advancing its clinical-stage product pipeline."

For an analyst ratings summary and ratings history on Prima Biomed click here. For more ratings news on Prima Biomed click here.

Shares of Prima Biomed closed at $1.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage